Jérémie Guedj

Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells

C. Passaes, A. Sáez-Cirión, V. Monceaux, 2024, Nature communications.

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

R. Greil, Y. Yazdanpanah, C. Marquette, 2021, The Lancet Infectious Diseases.

Treatment With Bulevirtide in HIV Infected patients With chronic Hepatitis Delta. ANRS HD EP01 BULEDELTA & Compassionate Cohort

V. de Lédinghen, O. Chazouilleres, C. Gaudy-Graffin, 2024, JHEP Reports.

Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection

Andrew T. Russo, F. Mentré, D. Grosenbach, 2023, PLoS biology.

Modeling SIV kinetics supports that cytotoxic response drives natural control and unravels heterogeneous populations of infected cells

C. Rouzioux, J. Guedj, C. Passaes, 2020, bioRxiv.

Antiviral capacity of the early CD8 T-cell response is predictive of natural control of SIV infection: Learning in vivo dynamics using ex vivo data.

C. Passaes, A. Sáez-Cirión, R. Le Grand, 2024, PLoS computational biology.

Antiviral capacity of the early CD8 T-cell response is predictive of natural control of SIV infection

C. Passaes, A. Sáez-Cirión, R. Le Grand, 2023, bioRxiv.

SARS-CoV-2 viral dynamics in infections with variants of concern in the French community

J. Guedj, F. Blanquart, Gina Cosentino, 2021 .

Modelling HIV-1 control and remission

Bharadwaj Vemparala, Jérémie Guedj, Narendra M Dixit, 2024, NPJ systems biology and applications.